Trilaciclib is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.\u00a0Trilaciclib, sold under the brand name Cosela, is a medication used to reduce the frequency of chemotherapy-induced bone marrow suppression. The most common side effects include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs (pneumonia).<\/p>\n
Trilaciclib may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin-dependent kinase 4\/6, a type of enzyme. Trilaciclib is the first therapy in its class and was approved for medical use in the United States in February 2021. The U.S. Food and Drug Administration considers it to be a first-in-class medication.<\/p>\n
If trilaciclib for injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Cosela (trilaciclib for injection) for intravenous use Initial U.S. Approval: 2021<\/p>\n","protected":false},"excerpt":{"rendered":"
Cosela (trilaciclib) is a medication to reduce the damage done on the bone marrow by chemotherapy (myelosuppression) in adult patients with extensive-stage small cell lung cancer (ES-SCLC) prior to receiving chemotherapy.<\/p>\n
Disease Indications-Lung Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201ctrilaciclib for injection\u201d based on the information you provide.<\/p>\n
\nManufacturer-G1 Pharmaceuticals, Inc.
\nUsage-Intravenous
\nMedicine Approved BY-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n